Skip to content
    IQV
    Earnings call· Jun 2025(Q2 FY25)

    IQVIA HOLDINGS Q2 FY25 earnings call IQV

    Jul 22, 2025 Source

    Executive summary

    IQVIA Q2 FY25 — Record Revenue and Strong Bookings Despite Unsettled Market

    IQVIA delivered a strong second quarter, achieving record revenue and robust net bookings, driven by strategic go-to-market efforts and strong performance in Technology & Analytics Solutions. Despite an unsettled market environment and persistent decision-making delays, the company expanded its R&DS backlog and saw significant uptick in RFP flow. Management is leveraging AI and cost controls to navigate pricing pressures and drive future efficiencies.

    Highlights

    5

    • Revenue exceeded the high end of guidance, reaching over $4 billion for the first time in company history.

    • Technology & Analytics Solutions (TAS) revenue grew 8.9% on a reported basis, led by double-digit growth in real-world evidence.

    • R&D Solutions (R&DS) net bookings were approximately $2.5 billion, translating to a net book-to-bill of 1.12x.

    • R&DS backlog reached a new record of over $32 billion, growing over 5% compared to the prior year.

    • Qualified pipeline was up high single digits sequentially and year-over-year, with RFP flow growing low teens year-over-year.

    Concerns

    5

    • The overall market environment remains unsettled, causing some delays in decision-making on new programs.

    • Gross margin experienced compression due to a 1/3 impact from FX tailwind and 2/3 from product mix shifts.

    • Pricing pressures persist in the R&DS market due to increased competition for a relatively smaller pie.

    • Decision timelines for clinical projects remain more elongated than usual.

    • Business and consulting within TAS are still below historical high single/double-digit growth trends, with recovery expected by end of FY26.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year FY25 Revenue
    $16.100 billion to $16.300 billion
    high materiality
    High
    Full-year FY25 Adjusted EBITDA
    $3.750 billion to $3.825 billion
    high materiality
    High
    Full-year FY25 Adjusted Diluted EPS
    $11.75 to $12.05
    high materiality
    High
    Q3 FY25 Revenue
    $4.025 billion and $4.100 billion
    medium materiality
    High
    Q3 FY25 Adjusted EBITDA
    $935 million to $955 million
    medium materiality
    High
    Q3 FY25 Adjusted Diluted EPS
    $2.92 and $3.02
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Technology & Analytics Solutions (TAS)
    Revenue exceeded expectations, driven by clients launching new drugs and executing commercial roadmaps. Real-world evidence was the strongest sub-segment.
    Constant Currency Growth: 6.8%Real-world evidence growth: double-digitData, consulting, and tech segments growth: low to mid-single digitsH1 Revenue: $3.174 billionH1 Reported Growth: 7.7%H1 Constant Currency Growth: 7.2%
    		$1.628 billion8.9%——
    R&D Solutions (R&DS)
    Performance improved despite an unsettled market, driven by intensified 'See More, Win More' strategy, leading to stronger bookings and record backlog.
    Constant Currency Growth: 1.3%Revenue ex-COVID Reported Growth: 4.2%Revenue ex-COVID Constant Currency Growth: 3%Net Bookings: $2.5 billionNet Book-to-Bill: 1.12xBacklog: $32.1 billion (up 5.1% YoY)Next 12 Months Revenue from Backlog: $8.1 billion (up 4.8% YoY)Qualified Pipeline Growth: high single digits (sequentially and YoY)RFP Flow Growth: low teens (YoY), high single digits (sequentially)Win Rate: improved significantly, especially in EBP segmentH1 Revenue: $4.303 billionH1 Reported Growth: 1.4%H1 Constant Currency Growth: 1.2%H1 Revenue ex-COVID Reported Growth: 3.1%H1 Revenue ex-COVID Constant Currency Growth: 3%
    		$2.201 billion2.5%——
    Contract Sales & Medical Solutions (CSMS)
    Delivered solid growth in the quarter.
    Constant Currency Growth: 6.4%H1 Revenue: $369 millionH1 Reported Growth: 2.2%H1 Constant Currency Growth: 1.9%
    		$188 million9.3%——

    Operational metrics

    32
    Total Revenue Growth
    5.3%YoY
    Q2 FY25

    Total company revenue growth for the second quarter.

    Total Revenue Growth ex-COVID
    6.3%YoY
    Q2 FY25

    Total company revenue growth excluding COVID-related work from both periods.

    Total Revenue Growth Constant Currency
    3.6%YoY
    Q2 FY25

    Total company revenue growth at constant currency.

    Total Revenue Growth ex-COVID Constant Currency
    4.6%YoY
    Q2 FY25

    Total company revenue growth excluding COVID-related work from both periods at constant currency.

    Adjusted EBITDA
    $910 millionup 2.6% YoY
    Q2 FY25

    Adjusted EBITDA for the second quarter.

    Adjusted Diluted EPS
    $2.81up 6.4% YoY
    Q2 FY25

    Adjusted diluted EPS for the second quarter.

    Total Revenue
    $7,846 millionup 3.9% reported
    H1 FY25

    Total company revenue for the first half.

    Adjusted EBITDA
    $1,793 million
    H1 FY25

    Adjusted EBITDA for the first half.

    GAAP Net Income
    $266 million
    Q2 FY25

    GAAP net income for the second quarter.

    GAAP Diluted EPS
    $1.54
    Q2 FY25

    GAAP diluted earnings per share for the second quarter.

    GAAP Net Income
    $515 million
    H1 FY25

    GAAP net income for the first half.

    GAAP Diluted EPS
    $2.94
    H1 FY25

    GAAP diluted earnings per share for the first half.

    Adjusted Net Income
    $486 million
    Q2 FY25

    Adjusted net income for the second quarter.

    Adjusted Net Income
    $965 million
    H1 FY25

    Adjusted net income for the first half.

    Adjusted Diluted EPS
    $5.50up 6.2% YoY
    H1 FY25

    Adjusted diluted earnings per share for the first half.

    Cash and Cash Equivalents
    $2.039 billion
    as of June 30, 2025

    Balance of cash and cash equivalents at quarter end.

    Gross Debt
    $15.490 billion
    as of June 30, 2025

    Gross debt balance at quarter end.

    Net Debt
    $13.451 billion
    as of June 30, 2025

    Net debt balance at quarter end.

    Net Leverage Ratio
    3.61x
    Q2 FY25

    Net leverage ratio at quarter end.

    Capital Expenditure
    $151 million
    Q2 FY25

    Capital expenditure for the second quarter.

    Share Repurchases
    $607 million
    Q2 FY25

    Amount of shares repurchased in the second quarter.

    Share Repurchases
    above $1 billion
    H1 FY25

    Total share repurchase activity for the first half.

    Remaining Repurchase Authorization
    approximately $2 billion
    Q2 FY25

    Remaining authorization under the current share repurchase program.

    Senior Notes Issued
    $2 billion
    Q2 FY25

    Issuance of senior notes in the second quarter.

    AI Agents in Production
    over 20
    Q2 FY25

    Number of AI agents developed and deployed into production.

    AI Agents in Development
    over 50
    Q3 FY25

    Number of AI agents currently under development for third quarter deployment.

    Literature Review Capacity Expansion via AI
    10x
    Q2 FY25

    Expansion of literature review capacity achieved through AI agents.

    Patient Journey Delivery Time Reduction via AI
    2/3from 12 weeks to 4 weeks
    Q2 FY25

    Reduction in delivery time for patient journeys using AI agents.

    Gross Margin Compression Drivers
    1/3 FX tailwind, 2/3 product mix
    Q2 FY25

    Breakdown of factors contributing to gross margin compression.

    FSP Proportion of Net Bookings
    very low single digits
    Q2 FY25

    Proportion of net bookings that are FSP (Functional Service Provider) in the second quarter.

    EBP Segment RFP Flow Growth
    low teensYoY
    Q2 FY25

    RFP flow growth for the Emerging Biotech and Pharma (EBP) segment.

    Large Pharma RFP Flow Growth
    low to mid-single digits
    Q2 FY25

    RFP flow growth for the large pharma segment.

    Industry KPIs

    5
    MetricValueDetails
    Revenue EPS guidanceRevenue $16.100B-$16.300B; Adjusted EPS $11.75-$12.05USD
    Pricing price realizationpricing pressures
    M a contribution synergies150 basis points%
    Clinical research cro bookings$2.5 billionUSD
    Segment organic revenue growthTAS 6.8%; R&DS 1.3%; CSMS 6.4%%

    Product announcements

    1
    ProductTypeDetails
    IQVIA Patient Engagement Applaunch

    Deals & partnerships

    7
    NVIDIACollaboration on AI agent development

    IQVIA is developing custom-built AI agents using NVIDIA technology designed to streamline processes, enhance workflows, and accelerate insights across the life sciences ecosystem. NVIDIA showcased IQVIA's platform at its European conference.

    Sarah Cannon Research Institute (SCRI)Strategic collaboration to transform oncology trials

    Aims to accelerate trial activation, boost recruitment, and streamline data capture of electronic health records by uniting IQVIA's global scale and connected intelligence with SCRI's deep community oncology expertise.

    Top 10 pharma client (Europe)Market access strategy for Type 1 diabetes therapy

    Selected IQVIA to advance their market access strategy for a breakthrough Type 1 diabetes therapy entering Europe, leveraging AI-driven insights and pricing expertise to shape value proposition, pricing, and contracting.

    European biotech clientGlobal launch support for novel oncology therapy

    Selected IQVIA to support the global launch of a novel oncology therapy, delivering a GenAI-powered assistant and HCP Persona insights to enable simulation of HCP behavior and precise targeting.

    Top 10 pharma client (U.S.)Strategic engagement for novel oncology therapy launch

    Awarded IQVIA a strategic engagement to support the launch of a novel oncology therapy in the U.S., delivering insights and technology infrastructure to ensure commercial success.

    Top 10 pharma clientGlobal real-world safety and effectiveness study for dermatology treatment

    Selected IQVIA to lead a global real-world safety and effectiveness study for a new dermatology treatment spanning 8 countries and 3,000 patients, to support product adoption and long-term evidence generation.

    European biotech companyGlobal observational study for rare disease therapy

    Awarded IQVIA a global observational study to assess the real-world safety and effectiveness of a rare disease therapy in kidney disorders, highlighting IQVIA's rare disease expertise and use of AI-enabled tools.

    Risks & headwinds

    4
    Unsettled Market EnvironmentOngoing

    Causing some delays in decision-making on new programs

    Mitigation: Intensifying 'See More, Win More' go-to-market strategy; clients eventually proceeding with critical programs.

    Pricing Pressures in R&DSShort to medium-term

    Competitors forcing price reductions; IQVIA willing to accept lower prices to win business

    Mitigation: Strategy to 'See More, Win More' to gain market share and build backlog; internal cost controls and AI-driven efficiencies to offset.

    Elongated Decision Timelines for Clinical ProjectsOngoing

    Decision timelines remain longer than usual

    Mitigation: Clients eventually proceeding with critical Phase III programs; IQVIA's proactive market engagement.

    Gross Margin CompressionNext couple of quarters

    1/3 due to FX tailwind, 2/3 due to product mix (higher growth in lower-margin real-world and FSP)

    Mitigation: Strong cost control at SG&A level; expectation of FSP proportion returning to historical levels over time.

    What to watch in Q3 FY25

    5

    R&DS large delayed trial resumption

    Latter part of FY25 (Q4 FY25)
    CurrentInitiation discussions underway
    TargetResumption of the trial

    Why it matters

    This large trial is expected to drive a larger-than-usual uptick in R&DS revenue in Q4 FY25.

    With respect to R&DS and the specifics of your question regarding that large delay trial that we said before was going to resume in the latter part of '25, and that's still on. And in fact, we're having initiation discussions with the clients, and that is still on as forecasted.

    Q&A highlights

    6

    How does TAS continue to perform well despite market uncertainty, and how does the current environment differ from when TAS faced headwinds and R&DS was strong?

    TAS recovery is strong, driven by new drug launches and commercial roadmaps, with real-world evidence being a key driver. R&DS intensified its 'See More, Win More' strategy to improve bookings despite unsettled market policies, noting that clients eventually proceed with critical programs.

    “Clients are continuing to execute in a regular way. They have commercial road maps and those require services.”

    asked by Unknown Analyst · answered by Ari Bousbib

    2 min read6 chapters

    Detailed Narrative

    01

    AI Strategy and Execution

    IQVIA is deeply committed to AI transformation, collaborating with NVIDIA to develop specialized AI agents. The company was recognized as a front-runner generative AI leader for life sciences by Everest Group. Currently, over 20 AI agents are in production across commercial, real-world, and R&DS use cases, with plans to deploy over 50 agents covering 15 use cases in Q3. These agents are driving significant efficiencies, such as a 10x expansion in literature review capacity and a 2/3 reduction in patient journey delivery time, demonstrating strong client interest and internal benefits.

    02

    TAS Business Momentum

    The Technology & Analytics Solutions (TAS) segment continued its strong recovery, exceeding expectations with 8.9% reported revenue growth in Q2. This performance is attributed to clients proceeding with new drug launches and executing commercial roadmaps despite broader market uncertainties. Real-world evidence was a standout performer with double-digit growth. Leading indicators, including a strong pipeline of opportunities, improved win rates, and shorter average time to close deals, suggest continued strength for TAS.

    03

    R&DS Market Adaptation and Bookings Strength

    Despite an unsettled market environment and persistent policy uncertainty, R&D Solutions (R&DS) achieved robust net bookings of $2.5 billion, resulting in a 1.12x net book-to-bill ratio. This was driven by IQVIA's intensified 'See More, Win More' go-to-market strategy, which involved expanding market reach, responding to more RFPs, and significantly improving win rates, particularly within the EBP segment. The qualified pipeline is up high single digits sequentially and year-over-year, indicating strong forward demand.

    04

    Oncology and Obesity Leadership

    IQVIA highlighted its leadership in key therapeutic areas, including oncology and obesity. The company announced a strategic collaboration with Sarah Cannon Research Institute to transform oncology trials globally and secured significant Phase III trial wins in colorectal, pancreatic, and MTS oncology. In obesity, IQVIA was selected to lead two global Phase III trials and is supporting a top 10 pharma client's next-generation GLP-1 development program, leveraging its vast footprint and expertise.

    05

    Cell & Gene Therapy and Decentralized Trials Innovation

    IQVIA is expanding its capabilities in advanced therapies, managing a significant gene editing program for Wilson disease that utilizes AI-enabled solutions for speed and precision. The company also received recognition for its innovation in decentralized trials, winning the Medtech Breakthrough Award for its patient engagement app. This app enhances patient access, engagement, and retention through multilingual support and strong privacy features, enabling participation from diverse geographic regions.

    06

    Gross Margin Dynamics and Cost Control

    Second-quarter gross margin experienced compression, with one-third attributed to FX tailwinds and two-thirds to product mix shifts. The mix impact resulted from higher growth in lower-margin real-world evidence within TAS and an increased proportion of pass-through and FSP revenues in R&DS. Despite these pressures, management emphasized strong cost control at the SG&A level, which helped to offset a significant portion of the gross margin compression.

    AI-generated summary of the company’s earnings call. Not investment advice.